AFFYMAX AND TAKEDA ANNOUNCE COMPREHENSIVE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF HEMATIDE FOR ANEMIA

A A

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced that the companies have entered into an exclusive global agreement to develop and commercialize Affymax's lead product candidate, Hematide, for the treatment of anemia.

Drug Newswire (http://www.drugnewswire.com/2679/)